Exposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries-data from the ECEE Network Group

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F19%3A10395958" target="_blank" >RIV/00669806:_____/19:10395958 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11140/19:10395958
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=SziHsH8ZXR" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=SziHsH8ZXR</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5603/GP.2019.0070" target="_blank" >10.5603/GP.2019.0070</a>

Jazyk výsledku
angličtina
Název v původním jazyce
Exposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries-data from the ECEE Network Group
Popis výsledku v původním jazyce
DTG exposure was reported in 415 women, of which 26 were during pregnancy. Of those, 22 were on DTG at the time of conception and 4 had started DTG during pregnancy. Four pregnancies were ongoing at the time of the study and of those with an outcome, 77.3% resulted with term, 13.6% preterm delivery, 4.5% spontaneous and 4.5% medical abortion. Countries with low- or moderate HIV prevalence should be included in studies reviewing pregnancy outcomes and in any surveillance system to ensure the accuracy of drug safety revision.
Název v anglickém jazyce
Exposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries-data from the ECEE Network Group
Popis výsledku anglicky
DTG exposure was reported in 415 women, of which 26 were during pregnancy. Of those, 22 were on DTG at the time of conception and 4 had started DTG during pregnancy. Four pregnancies were ongoing at the time of the study and of those with an outcome, 77.3% resulted with term, 13.6% preterm delivery, 4.5% spontaneous and 4.5% medical abortion. Countries with low- or moderate HIV prevalence should be included in studies reviewing pregnancy outcomes and in any surveillance system to ensure the accuracy of drug safety revision.

Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)